Payment overview · 2025
General Payments
$244.79
13 reported records · 8 companies
Healthcare provider profile · identity verified
Clayton Branton, MD
Allopathic & Osteopathic Physicians|Family Medicine · FARMERVILLE, LA · NPI 1669934857
Verified facts
What the public records show
CMS Open Payments records show Clayton Branton, MD received $244.79 in general payments during 2025 across 13 reported records.
Axsome Therapeutics, Inc. accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.53 | 25.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $50.34 | 20.6% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $30.32 | 12.4% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.65 | 9.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.92 | 8.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.56 | 8.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.56 | 8.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.91 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $244.79 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $61.53 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $50.34 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $30.32 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
144 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 367 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 84 |
| Potassium Chloride | Potassium Chloride | 272 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 66 |
| Losartan Potassium | Losartan Potassium | 245 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 230 | 80 |
| Lisinopril | Lisinopril | 174 | 50 |
| Furosemide | Furosemide | 161 | 58 |
| Omeprazole | Omeprazole | 156 | 56 |
| Farxiga | Dapagliflozin Propanediol | 144 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 45 |
| Mounjaro | Tirzepatide | 126 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 113 | 34 |
| Meloxicam | Meloxicam | 111 | 36 |
| Trazodone Hcl | Trazodone Hcl | 109 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 34 |
| Montelukast Sodium | Montelukast Sodium | 105 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 29 |
| Ozempic | Semaglutide | 97 | 21 |
| Eliquis | Apixaban | 91 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 30 |
| Famotidine | Famotidine | 88 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 28 |
| Metformin Hcl | Metformin Hcl | 84 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 36 |
| Linzess | Linaclotide | 77 | 16 |
| Metformin Hcl Er | Metformin Hcl | 72 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | suppressed |
| Trulicity | Dulaglutide | 71 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 24 |
| Ondansetron Odt | Ondansetron | 66 | 39 |
| Sertraline Hcl | Sertraline Hcl | 65 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 26 |
| Carvedilol | Carvedilol | 60 | 19 |
| Tramadol Hcl | Tramadol Hcl | 56 | 18 |
| Simvastatin | Simvastatin | 55 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 19 |
| Donepezil Hcl | Donepezil Hcl | 52 | 12 |
| Methylprednisolone | Methylprednisolone | 52 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 12 |
| Jardiance | Empagliflozin | 47 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 15 |
| Celecoxib | Celecoxib | 43 | 13 |
| Allopurinol | Allopurinol | 41 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 16 |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Fluconazole | Fluconazole | 37 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Bumetanide | Bumetanide | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 14 |
| Myrbetriq | Mirabegron | 36 | 12 |
| Kerendia | Finerenone | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 15 |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 21 |
| Finasteride | Finasteride | 26 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Prednisone | Prednisone | 25 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | 11 |
| Tradjenta | Linagliptin | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 16 | 11 |
| Novolog | Insulin Aspart | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Dotti | Estradiol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $244.79 · 13 records | Axsome Therapeutics, Inc. | Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, IBSRELA, Omnipod, TRINTELLIX, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error